Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response …
Context: Epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) are
considered to be effective treatments for advanced NSCLC patients with sensitizing EGFR …
considered to be effective treatments for advanced NSCLC patients with sensitizing EGFR …
[HTML][HTML] Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor …
T De Pas, F Toffalorio, M Manzotti, C Fumagalli… - Journal of Thoracic …, 2011 - Elsevier
Introduction Mutations of the epidermal growth factor receptor (EGFR) have been proven to
predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib …
predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib …
Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
M Takeda, I Okamoto, J Tsurutani, N Oiso… - Japanese journal of …, 2012 - academic.oup.com
Objective Somatic mutations in the epidermal growth factor receptor gene are associated
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non–small cell lung cancer
Purpose: Clinical features of epidermal growth factor receptor (EGFR) mutations, L858R,
deletions in exon 19, T790M, and insertions in exon 20, in non–small cell lung cancer …
deletions in exon 19, T790M, and insertions in exon 20, in non–small cell lung cancer …
Epidermal growth factor receptor mutations in non–small-cell lung cancer: Implications for treatment and tumor biology
PA Jänne, JA Engelman, BE Johnson - Journal of clinical oncology, 2005 - ascopubs.org
The epidermal growth factor receptor (EGFR) has emerged as an attractive therapeutic
target for patients with non–small-cell lung cancer (NSCLC). However, despite its almost …
target for patients with non–small-cell lung cancer (NSCLC). However, despite its almost …
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non–small cell lung cancer treated with epidermal growth …
PA Jänne, BE Johnson - Clinical cancer research, 2006 - AACR
Somatic mutations in the epidermal growth factor receptor (EGFR) have been identified in
patients with advanced non–small cell lung cancer who achieve dramatic clinical and …
patients with advanced non–small cell lung cancer who achieve dramatic clinical and …
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer
Background There are many complex and rare mutations in the epidermal growth factor
receptor (EGFR) gene in non-small cell lung cancer (NSCLC) other than the two classical …
receptor (EGFR) gene in non-small cell lung cancer (NSCLC) other than the two classical …
Antitumoral activity of tyrosine kinase inhibitors in patients with non-small cell lung cancer harbouring rare epidermal growth factor receptor mutations
M Oyaert, I Demedts, E Boone… - Molecular diagnosis & …, 2015 - Springer
Introduction Mutations in the epidermal growth factor receptor (EGFR) have been reported
as predictive markers of tumour response to tyrosine kinase inhibitors (TKIs) in patients with …
as predictive markers of tumour response to tyrosine kinase inhibitors (TKIs) in patients with …
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
SH Cho, LC Park, JH Ji, S Park, DW Hwang… - Cancer chemotherapy …, 2012 - Springer
Purpose The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs)
gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation …
gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation …
A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and …
RG Manzano, EM Navarro, E Eugenieva… - Clinical and …, 2008 - Springer
Most of the somatic epidermal growth factor receptor (EGFR) mutations described to date in
non-small-cell lung cancer (NSCLC) patients are located in the kinase domain and are …
non-small-cell lung cancer (NSCLC) patients are located in the kinase domain and are …